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EDITORIALPerioperative  bleeding  and  early  mortality  in  hip  and
knee  surgery
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[Bleeding,  deep  venous  thrombosis  and,  above  all,  cardiovas-
cular  accidents  are  the  more  severe  complications  of  major
orthopedic  surgery,  as  they  may  be  life-threatening.  Mor-
tality  at  3  months  following  total  hip  or  knee  replacement
was  0.9%  in  a  French  observational  study  of  1080  patients
[1].  Large-scale  registries  allow  precise  estimation:  mortal-
ity  was  0.24%  in  7665  under  60-year-old  in  the  Danish  registry
[2],  reaching  1.8%  in  the  6411  patients  operated  on  after
the  age  of  80  years.  Comorbidity  obviously  entails  increased
risk:  the  French  observational  ESCORTE  study  of  6860  cases
found  14.7%  mortality  at  6  months  following  hip  fracture,
one-third  of  which  was  from  cardiovascular  causes  and  1.6%
due  to  severe  bleeding  [3].  Lie  et  al.  [4]  reported  a  4-fold
elevation  of  risk  in  ﬁrst-line  hip  and  knee  surgery  in  71-to-
80  year-old  versus  50-to-60  year-old  patients,  with  mortality
concentrated  in  the  ﬁrst  month.
Two  risk  factors  seem  to  be  predominant:  overlooked
coronaropathy  (the  ‘‘silent  killer’’  unmasked  by  Devereaux
et  al.  in  the  POISE  study  [5])  and  bleeding.
The  consequences  of  bleeding  are  particularly  impor-
tant  as  hemoglobin  levels  are  brought  down  to  less  than
8  or  9  g/dl  in  patients  with  cardiovascular  history  [6].  This
conﬁrms  Eikelboom’s  ﬁndings,  in  anti-thrombotic  treatment
trials  [7],  of  a  7-fold  increase  in  mortality  associated  with
major  bleeding.
Allogeneic  transfusion  is  essential  in  restoring
hemoglobin  levels,  but  is  not  without  its  own  inherent
infectious,  immunologic  and  pulmonary  risks.
Blood-sparing  protocols  seek  to  reduce  the  need  for  allo-
geneic  erythrocyte  transfusion  while  conserving  adequate
hemoglobin  levels;  they  comprise  three  stages:
•  pre-operative,  ensuring  that  the  patient  comes  to  a
potentially  hemorrhagic  operation  with  an  ‘‘advance’’
able  to  cover  any  drop  in  hemoglobin  level;
•  postoperative,  by  recovery  of  discharged  blood  for  possi-
ble  retranfusion;
•  and  peroperative.
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as  described  20  years  ago  [8],  particularly  during  prepara-
ion  of  the  acetabulum  and,  even  more,  of  the  femur.  In  Total
nee  Replacement  (TKR),  this  peak  ﬁbrinolysis  affects  gen-
ral  circulation  when  the  tourniquet  is  released.  Fibrinolysis
ontinues  through  to  postoperative  hour  20;  peroperative
rophylaxis  should  therefore  be  implemented,  and  epsilon
minocaproic  acid  and  tranexamic  acid  have  been  studied
n  this  regard.  The  former  is  no  longer  available  in  Europe.
andomized  studies  of  tranexamic  acid  against  placebo  or
o  treatment  (19  studies,  999  patients)  demonstrated  a  one-
hird  reduction  in  blood  loss,  which  is,  obviously,  especially
igniﬁcant  in  severely  hemorrhagic  surgery.  The  two  studies
ublished  in  our  present  edition  conﬁrm  the  usefulness  of
ranexamic  acid  in  orthopedic  surgery;  the  technique  is  inex-
ensive,  and  may  naturally  ﬁnd  its  place  in  blood-sparing
trategies  during  potentially  hemorrhagic  operations,  help-
ng  avoid  the  severe  collateral  damage  that  can  beset  our
unctional  surgery.
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